Vertex Down 13% in 6 Months: Buy, Sell or Hold the Stock?
Those who already own the stock may retain it for some time to see if VRTX's CF sales continue to rise and how the Casgevy ...
Cantor Fitzgerald Reiterates Overweight Rating for Vertex Pharmaceuticals (NASDAQ:VRTX)
Vertex Pharmaceuticals (NASDAQ:VRTX – Get Free Report)‘s stock had its “overweight” rating restated by equities researchers ...
Benzinga.com14d
Vertex Pharmaceuticals Sets Sight on Expanding Portfolio with Alyftrek Approval, Pain Treatment Progress, and Diabetes Trials
FDA approval of ALYFTREK and TRIKAFTA expands CF treatment options ... If approved, it would give Vertex Pharmaceuticals a significant new revenue source beyond cystic fibrosis, especially as ...
Vertex Pharmaceuticals’ (VRTX) “Outperform” Rating Reaffirmed at William Blair
Vertex Pharmaceuticals (NASDAQ:VRTX – Get Free Report)‘s stock had its “outperform” rating reaffirmed by stock analysts at ...
Vertex stock price target cut to $533 by Piper Sandler
Piper Sandler made a slight adjustment to the price target of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX), bringing it down to $533 from the previous target of $535, while maintaining an ...
Cystic Fibrosis Therapeutics Market Booming Worldwide With Analysis, Growth, Upcoming Trend & Future Scope By 2033
The commitment of organizations like the Cystic Fibrosis Foundation to global research funding and access initiatives has further propelled market growth. Additionally, major pharmaceutical companies, ...